US: BRIBF - Brii Biosciences Limited

Rentabilidade por seis meses: +7.57%
Rendimento de dividendos: 0.00%

Cronograma de promoção Brii Biosciences Limited

Agenda avançada Gráfico simples
Financial Markets by TradingView

Sobre a empresa Brii Biosciences Limited

Brii Biosciences Limited engages in the research and development of therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, BRII-835, and BRII-877, which are in Phase 2 the development of a functional cure for HBV for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 2; and BRII-732 that is in Phase 1 clinical trial and BRII-753, which is in preclinical stage for the treatment of HIV.

mais detalhes
It develops BRII-296 for the treatment of PPD/MDD, anxiety, and other depressive disorders; BRII-297 for treatment of various depressive disorders; BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for oral treatment for patients with chronic NTM lung disease. Brii Biosciences Limited was incorporated in 2017 and is headquartered in Beijing, China.
Adicionar à lista de comparação
Adicionar à lista de observação
Adicionar ao portfólio
Adicionar aviso de preço

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета cny
Сайт https://www.briibio.com
Цена ао 0.1346
Alteração de preço por dia: +0.2972% (0.1346)
Alteração de preço por semana: +0.2972% (0.1346)
Alteração de preço por mês: +0.2972% (0.1346)
Alteração de preço em 3 meses: +7.57% (0.1255)
Mudança de preço em seis meses: +7.57% (0.1255)
Mudança de preço por ano: -41.28% (0.2299)
Mudança de preço em 3 anos: -93.81% (2.18)
Mudança de preço desde o início do ano: +7.57% (0.1255)
Todos os parâmetros

Subestimação

Nome Significado Nota
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0 0
Total: 2.5

Eficiência

Nome Significado Nota
ROA, % 0 0
ROE, % 0 0
Total: 0

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 0

Obrigação

Nome Significado Nota
Debt/EBITDA 0 10
Total: 10

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % -78.73 0
Rentabilidade Ebitda, % -67.51 0
Rentabilidade EPS, % -95.34 0
Total: 2
Mais detalhes

Supervisor Cargo Pagamento Ano de nascimento
Dr. Zhi Hong Ph.D. Co-founder, Executive Chairman of the Board & CEO 1964 (61 ano)
Dr. Ankang Li C.F.A., J.D., Ph.D. Chief Financial & Strategy Officer, Company Secretary and Executive Director 1979 (46 anos)
Dr. Eleanor de Groot Ph.D. Chief Technology Officer 1969 (56 anos)
Dr. Brian Alvin Johns Ph.D. Chief Scientific Officer
Sarah Qiu Associate Director of Investor Relations
Ms. Karen Del Barrio Neuendorff Chief People Officer & Head of Human Resources 1976 (49 anos)
Mr. Coy Stout Head of Patient Advocacy 1972 (53 ano)
Dr. Lianhong Xu Ph.D. Head of Discovery 1967 (58 anos)
Dr. Qing Zhu Ph.D. Head of China Research & Development 1968 (57 anos)
Dr. David Margolis M.D., M.P.H. Chief Medical Officer 1975 (50 anos)

Endereço: China, Beijing, Building 7 International Science Park - abrir no Google Maps, abrir mapas Yandex
Site: https://www.briibio.com